Anticoagulant and antiplatelet combination

This page covers all Anticoagulant and antiplatelet combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Factor Xa (rivaroxaban); Cyclooxygenase (aspirin), Factor Xa (rivaroxaban); P2Y12 receptor (ticagrelor), Thrombin, Factor Xa, COX-1.

Targets

Factor Xa (rivaroxaban); Cyclooxygenase (aspirin) · Factor Xa (rivaroxaban); P2Y12 receptor (ticagrelor) · Thrombin, Factor Xa, COX-1

Marketed (2)

• Rivaroxaban and aspirin 80 · Shiraz University of Medical Sciences · Cardiovascular
  This combination uses rivaroxaban to inhibit Factor Xa in the coagulation cascade while aspirin inhibits platelet aggregation, providing dual anticoagulant and antiplatelet effects.
• rivaroxaban and ticagrel therapy · Beijing Anzhen Hospital · Cardiovascular
  Rivaroxaban and ticagrelor together provide dual anticoagulation and antiplatelet therapy to prevent thrombotic events.

Phase 3 pipeline (1)

• Heparin & aspirin · Dr.Vandana Bansal · Cardiovascular
  Heparin and aspirin work synergistically to prevent blood clots by inhibiting coagulation cascade and platelet aggregation respectively.